Search

Gossamer Bio Inc

Slēgts

SektorsVeselības aprūpe

0.15 -11.76

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.15

Max

0.16

Galvenie mērījumi

By Trading Economics

Ienākumi

574K

-47M

Pārdošana

3.2M

17M

EPS

-0.17

Peļņas marža

-275.223

Darbinieki

161

EBITDA

2.1M

-44M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+613.33% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 17. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

6.6M

86M

Iepriekšējā atvēršanas cena

11.91

Iepriekšējā slēgšanas cena

0.15

Gossamer Bio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. aug. 00:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, though no specific news explains the movement. The price remains below its 20-day moving average.

2026. g. 14. aug. 22:51 UTC

Gossamer Bio Inc. shares are higher in after-market hours, despite disappointing U.S. retail sales data influencing broader market sentiment.

2026. g. 13. aug. 23:01 UTC

News

Gossamer Bio reported second-quarter net income of $16.9 million and plans to submit a New Drug Application for seralutinib in September 2026. Shares are higher in after-market trading.

2026. g. 12. aug. 23:01 UTC

Gossamer Bio Inc. shares advanced in after-market trading, continuing a strong performance since July 13, despite earlier fluctuations during the session.

2026. g. 11. aug. 23:11 UTC

No specific news was identified for Gossamer Bio Inc. in after-market trading, with shares effectively unchanged since Tuesday's close.

2026. g. 10. aug. 23:01 UTC

Gossamer Bio Inc. shares are higher in after-hours trading, reflecting strong performance and positioning above the 20-day moving average. No specific news was identified.

2026. g. 7. aug. 19:56 UTC

Gossamer Bio Inc shares are higher today amid a weaker jobs report, easing interest rate hike concerns and shifting market sentiment towards a dovish outlook.

2026. g. 6. aug. 23:12 UTC

Gossamer Bio Inc. shares are effectively unchanged in after-market trading, remaining flat within a narrow band. The stock is above its 20-day moving average.

2026. g. 5. aug. 23:36 UTC

Gossamer Bio Inc shares are higher in after-market trading, despite no specific news. The stock is also above its 20-day moving average.

2026. g. 4. aug. 23:01 UTC

Gossamer Bio shares declined after-market, reflecting broader market trends amid falling crude oil prices. Volatility was noted with fluctuations in trading.

2026. g. 3. aug. 23:06 UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

2026. g. 1. aug. 00:02 UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

2026. g. 31. jūl. 23:41 UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

2026. g. 30. jūl. 23:02 UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

2026. g. 29. jūl. 22:31 UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

2026. g. 28. jūl. 23:41 UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

2026. g. 27. jūl. 23:51 UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

2026. g. 24. jūl. 22:01 UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

2026. g. 23. jūl. 23:01 UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

2026. g. 22. jūl. 23:01 UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

2026. g. 21. jūl. 21:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

2026. g. 20. jūl. 23:01 UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Salīdzinājums

Cenas izmaiņa

Gossamer Bio Inc Prognoze

Cenas mērķis

By TipRanks

613.33% augšup

Prognoze 12 mēnešiem

Vidējais 1.07 USD  613.33%

Augstākais 2 USD

Zemākais 0.28 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Gossamer Bio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

5 ratings

2

Pirkt

2

Turēt

1

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
help-icon Live chat